Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Hunts For Biotech Partner In China; Calls Off Deal With India's Avesthagen

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - An inordinate delay in the development of three to four biopharmaceuticals by Bangalore-based Avesthagen has led Cipla - India's biggest company in the domestic market - to call off a five-year old partnership and look for joint ventures or collaborations with potential Chinese companies. The disclosure was made to shareholders by Cipla Chairman Yusuf Hamied, at the much-awaited annual general meeting of the company

You may also be interested in...



Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research

MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens

Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research

MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens

Cipla Forms Joint Venture Company With Chinese Firm For Biosimilars Foray

MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company

Related Content

UsernamePublicRestriction

Register

SC072594

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel